Tamoxifen (‘Nolvadex’): a review
Abstract
Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women. It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tamoxifen is a well-established drug.
“Tamoxifen is a well-established drug and is thus a promising candidate for a drug to regenerate myelin, as it will not require extensive safety testing.”
From Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system (2016) · cites this paper as [23]
Tamoxifen has been used for the treatment of breast cancer since the early 1970s.
“Tamoxifen has been used for the treatment of breast cancer since the early 1970s23.”
From Tamoxifen accelerates the repair of demyelinated lesions in the central nervous system (2016) · cites this paper as [23]
The citation lists haven’t been fetched yet
References 141 · Cited by 229
- Authors
- Clemons, M., Danson, S., & Howell, A.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- The Christie Hospital (GB)
- Corresponding author
- Clemons, M
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 28
- Issue
- 4
- Pages
- 165-180
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2080073879
- Cited by
- 229
- References
- 141
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 8 · 2023: 7 · 2022: 9 · 2021: 18 · 2020: 10 · 2019: 10 · 2018: 10 · 2017: 14 · 2016: 9 · 2015: 12 · 2014: 8 · 2013: 9 · 2012: 14
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Treatment Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
- Keywords
- tamoxifen, breast cancer, estrogen receptor-positive breast cancer, endocrine therapy, breast cancer chemoprevention, ductal carcinoma in situ, early breast cancer, aromatase inhibitors, treatment duration, tolerability
- MeSH terms
- Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Enzyme Inhibitors, Estrogen Antagonists, Female, Humans, Tamoxifen, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
